Persistent Off-the-Shelf meACE2-CAR-IL-15 NK Cells Derived from CD34(+) Cord Blood Stem Cells to Prevent and Treat COVID-19
Grant Award Details
Grant Type:
			
		Grant Number:
			DISC2COVID19-11947
		Investigator(s):
			Disease Focus:
			
		Human Stem Cell Use:
			
		Award Value:
			$150,000
		Status:
			Closed
		Progress Reports
Reporting Period:
			Year 1
		Grant Application Details
Application Title:
			Persistent Off-the-Shelf meACE2-CAR-IL-15 NK Cells Derived from CD34(+) Cord Blood Stem Cells to Prevent and Treat COVID-19
Public Abstract:
			Research Objective
To develop and characterize meACE-2-CAR-IL15 NK cells expressing a mutated ACE2 and IL-15, allowing specific killing of SARS-CoV-2-infected cells and long in vivo persistence of the engineered cells.
Impact
To provide a timely, novel, and effective cell therapy for COVID-19, which has no FDA-approved vaccines and only remdesivir has received an emergency-use approval.
Major Proposed Activities
		To develop and characterize meACE-2-CAR-IL15 NK cells expressing a mutated ACE2 and IL-15, allowing specific killing of SARS-CoV-2-infected cells and long in vivo persistence of the engineered cells.
Impact
To provide a timely, novel, and effective cell therapy for COVID-19, which has no FDA-approved vaccines and only remdesivir has received an emergency-use approval.
Major Proposed Activities
- To further optimize expansion of umbilical cord blood (UCB) hematopoietic stem cells (HSCs) and engineer the expanded with the meACE2-CAR-IL15 retrovirus.
 - To differentiate UCB HSCs transduced with meACE2-CAR-IL15 into NK cells, followed by cell expansion.
 - Proof of concept: In vitro evaluation of meACE2-CAR-IL15 NK cells.
 - Proof of concept: In vivo evaluation of meACE2-CAR-IL15 NK cells.
 - Manuscript submission for publication & preparation for an INTERACT meeting with the FDA.
 - N/A
 
Statement of Benefit to California:
			SARS has presented as a major public health threat in the past. A new SARS, COVID-19, started in December 2019 has rapidly disseminated to worldwide including California with mortality as high as 20% in the elderly and other more vulnerable populations. At present, worldwide COVID-19 patients have over 3.6 million with over 250,000 deaths. Currently, there are no approved COVID-19 vaccines and only remdesivir has received an FDA-approval for the treatment of COVID-19.